18F-DOPA-PET/CT role in medullary thyroid cancer patients with biochemical incomplete response
Clicks: 1
ID: 313803
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #74 of 91 articles by views in european journal of endocrinology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVE: Several patients with medullary thyroid carcinoma (MTC) are not cured after surgery. Disease persistence/recurrence is monitored by measuring calcitonin (CTN) and carcinoembryonic antigen (CEA) and by imaging. The role of 18F-fluoro-dihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA-PET/CT) in identifying structural disease in patients with biochemical incomplete response (BiR) remains debated. This study aimed to evaluate the capability of 18F-DOPA-PET/CT to identify structural disease in MTC patients with BiR. METHODS: We performed 18F-DOPA-PET/CT in 91 MTC patients with BiR without evidence of structural disease or indeterminate lesions on neck ultrasound (US) and total-body computed tomography (CT). RESULTS: 18F-DOPA-PET/CT showed pathological uptake in 16/37 (43.2%) CT-negative cases and in 43/54 (79.6%) CT-indeterminate cases. Of these, 23/43 (53.5%) cases showed concordance between 18F-DOPA-PET/CT uptake and CT-scan indeterminate lesions, 4/43 (9.3%) cases showed discordance, and 16/43 (37.2%) cases showed partial concordance. Moreover, 18F-DOPA-PET/CT showed pathological uptake in cervical lymph nodes in 33/91 (36.3%) cases, of whom 9 (27.3%) had no lesions at neck US, and 24 (72.7%) had indeterminate findings. Patients with positive 18F-DOPA-PET/CT showed higher median CTN and CEA values. Management of patients with positive ¹⁸F-DOPA PET/CT uptake did not change, except for those with bone metastases. CONCLUSIONS: 18F-DOPA-PET/CT demonstrates good diagnostic accuracy for identifying structural disease in MTC patients with BiR, particularly when indeterminate lesions are present on neck US and CT. However, in most BiR patients, the results of 18F-DOPA-PET/CT did not change their management.
| Reference Key |
openalex_W7160901743
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Carla Gambale, Alessio Faranda, Alice Ambrogio, Alessandro Prete, Elisa Minaldi, Virginia Cappagli, Duccio Volterrani, Rossella Elisei, Antonio Matrone |
| Journal | european journal of endocrinology |
| Year | 2026 |
| DOI |
10.1093/ejendo/lvag078
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.